- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Acrivon Therapeutics Announces $130 Million Private Placement Financing
- Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
- Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
- Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
- Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
More ▼
Key statistics
As of last trade, Acrivon Therapeutics Inc (ACRV:NMQ) traded at 8.56, 168.34% above the 52 week low of 3.19 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.58 |
---|---|
High | 8.71 |
Low | 8.28 |
Bid | 8.42 |
Offer | 8.54 |
Previous close | 8.36 |
Average volume | 165.87k |
---|---|
Shares outstanding | 30.88m |
Free float | 18.40m |
P/E (TTM) | -- |
Market cap | 258.12m USD |
EPS (TTM) | -2.73 USD |
Data delayed at least 15 minutes, as of May 15 2024 20:26 BST.
More ▼